Derivation of machine learning histologic scores correlating with portal pressures and the development of varices in NASH patients with cirrhosis

during hospitalization ( p = 0.012); however, this did not remain significant after adjusting for FIPS.Overall, 91 patients (40.3%) were still on NSBB treatment at the time of hospital discharge.NSBB therapy at discharge was neither linked to survival nor to development of AKI, ACLF or incidence of infections during further follow-up in the univariable and multivariable analysis.Conclusion: Intake of NSBB prior to TIPS is not linked to the risk of periinterventional complications.Use of NSBB after TIPS has no impact on the risk for AKI, ACLF, infections and mortality.Thus, NSBB may be stopped in patients achieving sufficient pressure reduction after TIPS.